Accumulating evidence from genetic and pharmacological interventions targeted toward DPP4 proteolytic function in animal models of disease seems to indicate that salutary effects including in heart failure and in totality seem to suggest the possibility of beneficial cardiovascular effects in patients. The gene discussed is DPP4; the disease is heart failure.